Expert Insights

Sara Tolaney, MD, discusses results from AMEERA-3, an open-label randomized phase 2 trial that explored amcenestrant vs physician’s choice of endocrine therapy in patients with endocrine-resistant ER-positive, HER2-negative advanced breast...

Denis Soulières, MD, discusses long-term follow-up data from the phase 3 KEYNOTE-040 and KEYNOTE-048 clinical trials examining pembrolizumab for patients with head and neck squamous cell carcinoma.

Joseph Renzulli, MD, discusses findings from the phase 2 ENACT trial, evaluating enzalutamide monotherapy vs active surveillance in patients with low- or intermediate-risk localized prostate cancer.

Erika Hamilton, MD, shares insights about the recent FDA approval of trastuzumab deruxtecan for patients with HER2-low metastatic breast cancer and the data that led to this approval.

Neal Shore, MD, shares insights about the recent FDA approval of darolutamide plus ADT and docetaxel for patients with metastatic hormone-sensitive prostate cancer and the data that led to this approval.

David Ilson, MD, PhD, discusses the role of radiotherapy in treating gastroesophageal junction cancer, which he presented at the Great Debates & Updates in Gastrointestinal Malignancies meeting.

Rachna Shroff, MD, highlights recent developments in the treatment of cholangiocarcinoma, including updates in novel and targeted therapies, during her presentation at the Great Debates and Updates in Gastrointestinal Malignancies meeting.

Christopher Ryan, MD, discusses findings from the phase 3 EVEREST trial, which investigated the effect of adjuvant treatment, everolimus, an mTOR inhibitor, on recurrence-free survival in patients receiving nephrectomy for renal cell...

Prof Vijay Maruti Patil, MBBS, MD, DM, discusses findings from a phase 3 trial that explored the use of docetaxel as a radiosensitizer in patients with head and neck cancer unsuitable for cisplatin-based chemoradiation.